Naltrexone and pharmacy benefit management

Journal of Addictive Diseases
Katherine M Harris, Cindy Thomas

Abstract

Naltrexone was approved by the FDA in 1994 for the treatment of alcohol dependence. Despite the potential to make treatment more effective and accessible, naltrexone use remains low by almost any measure. While many of the factors responsible for the slow pace of diffusion are unique to naltrexone and to the organization and delivery of alcohol treatment services, other factors are the same as those that affect the use of prescription medications more generally. Access to third-party coverage and formulary inclusion are necessary conditions for the adoption and diffusion of any new pharmaceutical technology. This paper describes current issues in drug benefit design and formulary coverage decisions, reviews publicly available information on naltrexone coverage by large health insurance programs and pharmaceutical benefit management companies, and examines whether drug benefit design constitutes a barrier to naltrexone use. Our review suggests that naltrexone is widely covered on public and private health plan formularies, though restrictions on use (i.e., quantity limits, prior authorization) are common.

References

Jan 1, 1992·Health Affairs·J A Rogowski
Jan 1, 1991·Health Affairs·M R Pollard, J M Coster
Oct 10, 1991·The New England Journal of Medicine·S B SoumeraiI Choodnovskiy
May 15, 1996·Annals of Internal Medicine·K A SchulmanD P Sulmasy
Jan 1, 1995·Health Affairs·S M Butler, R E Moffit
Jul 1, 1997·Health Affairs·N J Wilson, K W Kizer
Apr 20, 1999·JAMA : the Journal of the American Medical Association·J C GarbuttF T Crews
Mar 10, 2001·JAMA : the Journal of the American Medical Association·R TamblynL Mallet
Jul 14, 2001·Recent Developments in Alcoholism : an Official Publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism·C M HorganM T Lee
Sep 18, 2001·Health Affairs·J Tilly, J M Wiener
Dec 14, 2001·The New England Journal of Medicine·J H KrystalUNKNOWN Veterans Affairs Naltrexone Cooperative Study 425 Group
Dec 14, 2001·The New England Journal of Medicine·R K Fuller, E Gordis
Jul 11, 2002·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Wolfgang HannöverUlrich John
Mar 21, 2003·Journal of Substance Abuse Treatment·Cindy Parks ThomasRobert Swift
May 20, 2003·Addiction·Tami L MarkScott Crosse

❮ Previous
Next ❯

Citations

Oct 18, 2007·Expert Review of Neurotherapeutics·Paolo MannelliAshwin A Patkar
May 15, 2007·Journal of Substance Abuse Treatment·Constance M HorganElizabeth L Merrick
May 6, 2008·Health Services Research·Carolyn J Heinrich, Carolyn J Hill
Jul 17, 2013·Health Services Research·Carolyn J Heinrich, Grant R Cummings
Jul 26, 2005·Peptides·Richard J Bodnar, Gad E Klein
Jul 11, 2016·Drug and Alcohol Dependence·Kirsten C MorleyPaul S Haber
May 22, 2017·Journal of Substance Abuse Treatment·Hélène Chokron GarneauSuzette Glasner

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.